An oncology upstart with some deep-pocket VC connections has a unicorn-sized venture round to back the pipeline
These days it takes quite a bit of venture cash to turn heads, but Erasca can now join a short list of unicorn plays that managed it.
The San Diego cancer upstart — which has been long on money and short on biology from the start — has pieced together a $200 million B round from some of the deepest pockets in the field.
That would beat out all but the top 2 venture rounds of 2019, as cash coursed through the industry from every direction.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.